
Celgene options rights to Abide's serine hydrolase program; could acquire the company; deal terminated
Executive Summary
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes M&A Option
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com